142 related articles for article (PubMed ID: 28123854)
1. Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients.
Roh MR; Park KH; Chung KY; Shin SJ; Rha SY; Tsao H
Am J Cancer Res; 2017; 7(1):134-138. PubMed ID: 28123854
[TBL] [Abstract][Full Text] [Related]
2.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
3. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
Griewank KG; Murali R; Puig-Butille JA; Schilling B; Livingstone E; Potrony M; Carrera C; Schimming T; Möller I; Schwamborn M; Sucker A; Hillen U; Badenas C; Malvehy J; Zimmer L; Scherag A; Puig S; Schadendorf D
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25217772
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas.
Vazquez Vde L; Vicente AL; Carloni A; Berardinelli G; Soares P; Scapulatempo C; Martinho O; Reis RM
Melanoma Res; 2016 Apr; 26(2):93-9. PubMed ID: 26709572
[TBL] [Abstract][Full Text] [Related]
5. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.
Macerola E; Loggini B; Giannini R; Garavello G; Giordano M; Proietti A; Niccoli C; Basolo F; Fontanini G
Virchows Arch; 2015 Aug; 467(2):177-84. PubMed ID: 26055532
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutation subtypes and survival in stage I and II melanoma patients.
Andrés-Lencina JJ; Rachakonda S; García-Casado Z; Srinivas N; Skorokhod A; Requena C; Soriano V; Kumar R; Nagore E
Int J Cancer; 2019 Mar; 144(5):1027-1036. PubMed ID: 30070694
[TBL] [Abstract][Full Text] [Related]
7. Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients.
Ofner R; Ritter C; Heidenreich B; Kumar R; Ugurel S; Schrama D; Becker JC
J Cancer Res Clin Oncol; 2017 Apr; 143(4):613-617. PubMed ID: 27990595
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutation is uncommon in acral lentiginous melanoma.
Liau JY; Tsai JH; Jeng YM; Chu CY; Kuo KT; Liang CW
J Cutan Pathol; 2014 Jun; 41(6):504-8. PubMed ID: 24588324
[TBL] [Abstract][Full Text] [Related]
9. TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma Patients.
Del Bianco P; Stagni C; Giunco S; Fabozzi A; Elefanti L; Pellegrini S; Vecchiato A; Pigozzo J; Zamuner C; De Rossi A; De Nicolo A; Menin C
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32290374
[TBL] [Abstract][Full Text] [Related]
10. Melanomas of unknown primary frequently harbor TERT-promoter mutations.
Egberts F; Krüger S; Behrens HM; Bergner I; Papaspyrou G; Werner JA; Alkatout I; Haag J; Hauschild A; Röcken C
Melanoma Res; 2014 Apr; 24(2):131-6. PubMed ID: 24463461
[TBL] [Abstract][Full Text] [Related]
11. Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk.
Rachakonda S; Kong H; Srinivas N; Garcia-Casado Z; Requena C; Fallah M; Heidenreich B; Planelles D; Traves V; Schadendorf D; Nagore E; Kumar R
Genes Chromosomes Cancer; 2018 Nov; 57(11):564-572. PubMed ID: 30203894
[TBL] [Abstract][Full Text] [Related]
12. Frequency of telomerase reverse transcripter promoter mutations in desmoplastic melanoma subtypes: analyses of 76 cases.
Yang S; Leone D; Frydenlund N; Hoang M; Deng A; Hernandez-Perez M; Biswas A; Singh R; Yaar R; Mahalingam M
Melanoma Res; 2016 Aug; 26(4):361-6. PubMed ID: 27244099
[TBL] [Abstract][Full Text] [Related]
13. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.
Li Y; Cheng HS; Chng WJ; Tergaonkar V
Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14402-14407. PubMed ID: 27911794
[TBL] [Abstract][Full Text] [Related]
14. Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs).
Campanella NC; Celestino R; Pestana A; Scapulatempo-Neto C; de Oliveira AT; Brito MJ; Gouveia A; Lopes JM; Guimarães DP; Soares P; Reis RM
Eur J Hum Genet; 2015 Jun; 23(6):877-9. PubMed ID: 25248398
[TBL] [Abstract][Full Text] [Related]
15. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients.
Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O
Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032
[TBL] [Abstract][Full Text] [Related]
16. TERT Promoter Mutations and Telomerase in Melanoma.
Guo Y; Chen Y; Zhang L; Ma L; Jiang K; Yao G; Zhu L
J Oncol; 2022; 2022():6300329. PubMed ID: 35903534
[TBL] [Abstract][Full Text] [Related]
17.
Park HS; Kim JH; Cho MY; Chung KY; Roh MR
Ann Dermatol; 2021 Feb; 33(1):18-25. PubMed ID: 33911808
[TBL] [Abstract][Full Text] [Related]
18. Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA.
Diefenbach RJ; Lee JH; Stewart A; Menzies AM; Carlino MS; Saw RPM; Stretch JR; Long GV; Scolyer RA; Rizos H
Front Oncol; 2022; 12():820510. PubMed ID: 35494035
[TBL] [Abstract][Full Text] [Related]
19. Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.
Thomas NE; Edmiston SN; Tsai YS; Parker JS; Googe PB; Busam KJ; Scott GA; Zedek DC; Parrish EA; Hao H; Slater NA; Pearlstein MV; Frank JS; Kuan PF; Ollila DW; Conway K
Am J Dermatopathol; 2019 Apr; 41(4):264-272. PubMed ID: 30211730
[TBL] [Abstract][Full Text] [Related]
20. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
Schwaederle M; Krishnamurthy N; Daniels GA; Piccioni DE; Kesari S; Fanta PT; Schwab RB; Patel SP; Parker BA; Kurzrock R
Cancer; 2018 Mar; 124(6):1288-1296. PubMed ID: 29211306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]